News

Key to herbicide resistance
Enlarge image

ResearchUK

Key to herbicide resistance

26.03.2013 - British researchers have found that one single protein seems to control resistance against multiple herbicides of cereal crops weeds.

Multiple-herbicide resistance (MHR) in black-grass and annual rye-grass is a global threat for agriculture, leading to loss of chemical weed control in cereal crops. Until now, it was only poorly understood why MHR is associated with an enhanced ability to detoxify xenobiotics. Assuming an analogy with multiple drug resistance, which occurs in human tumours, researchers from York University and Syngenta now report they have found a possible explanation.

When they searched in black-grass and annual rye-grass for a plant homologue to the MDR causing phi glutathione S transferase (GSTP1) they found an enzyme that also showed both detoxification and signalling. When expressed in Arabidopsis thaliana, the protein termed GSTF1 led to multiple herbicide resistance in the model organism and showed a similar secondary metabolism pattern as the weeds. Those were not associated with a differential gene expression pattern but directly caused by GSTF1.

When they applied the GSTP1 blocker 4-chloro-7-nitro-benzoxadiazole to the weeds, the MHR masterswitch was blocked. They conclude that overexpression of GSTF1 orchestrates multi-herbicide resistance in grass weeds and that targeting the protein is a promising approach to regain weed control in cereal crops.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/masterswitch-for-herbicide-resistance.html

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%
  • ADDEX3.19 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.98 EUR0.00%
  • ACTELION113.50 CHF0.00%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014